skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.12d (Release date: 2017-12-26)
SearchBox Top
SearchBox Bottom
Pegvisomant (Code C61881)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Pegvisomant

Definition: A pegylated, recombinant, human growth hormone (GH) structural analog with GH receptor antagonist activity. As a GH analog, the structure of pegvisomant is similar to that of native GH with the exception of 9 amino acid substitutions. Pegvisomant selectively binds to GH receptors on cell surfaces, interfering with endogenous GH receptor binding and so GH signal transduction. Inhibition of GH signal transduction results in decreased serum concentrations of insulin-like growth factor-I (IGF-I), and other GH-responsive serum proteins, including IGF binding protein-3 (IGFBP-3) and the acid-labile subunit (ALS), and may inhibit the growth of cancers in which IGF-1 is upregulated.

Display Name: Pegvisomant

Label: Pegvisomant

NCI Thesaurus Code: C61881 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C0913469  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Somatotropin (18-Aspartic Acid, 21-Asparagine, 120-Lysine, 167-Asparagine, 168-Alanine, 171-Serine, 172-Arginine, 174-Serine, 179-Threonine) (Human), Pegylated

External Source Codes: 
CAS Registry Number 218620-50-9 (see NLM ChemIDplus info)
PDQ Closed Trial Search ID 655949
PDQ Open Trial Search ID 655949 (check for NCI PDQ open clinical trial info)
UMLS CUI C0913469

Other Properties:
     Name Value (qualifiers indented underneath)
code C61881
Contributing_Source CTRP
Contributing_Source FDA
Legacy_Concept_Name Pegvisomant
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom